Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
Arch Pediatr ; 22(6): 605-7, 2015 Jun.
Artículo en Francés | MEDLINE | ID: mdl-26014646

RESUMEN

In humans, Salmonella most often causes self-limiting gastroenteritis, but more severe symptoms such as sepsis and meningitis can also occur and can sometimes have a fatal outcome. Even if the meningitis is not fatal, sequelae such as epilepsy, cranial nerve palsies, and hydrocephalus can occur. In the United States, it has been estimated that approximately 6% of the human cases of salmonellosis can be attributed to contact with reptiles or amphibians. The infection may take place by direct contact between reptile and human or indirectly via contact with an environment contaminated with Salmonella from a reptile. Salmonella enterica subsp. enterica serotype Vitkin is a common gut inhabitant of reptiles. Though human cases due to this organism are exceedingly rare, it may infect young infants and immunocompromised individuals with a history of intimate associations with reptiles. Gastroenteritis is the most common presentation ; others include peritonitis, meningitis and bacteremia. We report a case of meningitis caused by S. enterica subsp. enterica serotype Vitkin in a 1-month-old child due to a pet turtle.


Asunto(s)
Meningitis Bacterianas/microbiología , Infecciones por Salmonella/etiología , Salmonella enterica , Animales , Humanos , Lactante , Masculino , Mascotas/microbiología , Salmonella enterica/aislamiento & purificación , Tortugas/microbiología
3.
Euro Surveill ; 18(24)2013 Jun 13.
Artículo en Inglés | MEDLINE | ID: mdl-23787161

RESUMEN

In May 2013, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection was diagnosed in an adult male in France with severe respiratory illness, who had travelled to the United Arab Emirates before symptom onset. Contact tracing identified a secondary case in a patient hospitalised in the same hospital room. No other cases of MERS-CoV infection were identified among the index case's 123 contacts, nor among 39 contacts of the secondary case, during the 10-day follow-up period.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Viaje , Trazado de Contacto , Coronavirus/aislamiento & purificación , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/transmisión , Transmisión de Enfermedad Infecciosa/prevención & control , Resultado Fatal , Francia , Humanos , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/prevención & control , Infecciones del Sistema Respiratorio/transmisión , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Emiratos Árabes Unidos
4.
Med Mal Infect ; 40(4): 232-7, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19959309

RESUMEN

BACKGROUND: Adequate glycopeptide use is necessary to optimize efficacy and minimize adverse events and selection of drug resistant microorganisms. METHODS: We performed a multicenter prospective observational study of glycopeptides indications based on modified HICPAC criteria, and quality of prescription based on French consensus recommendations. We assessed the adequacy of indications, loading dose, maintenance dose, administration frequency, serum monitoring and its consequences. RESULTS: We evaluated 117 curative adult prescriptions from nine hospitals. Glycopeptide indications were adequate in 71% with either a clinical (55%) or microbiological justification (27%). The indication was more frequently adequate for vancomycin than for teicoplanin (77% vs. 60%, p=0.04). De-escalation therapy was performed in 48% of all documented infections and 78% of documented infections with betalactam susceptible strains. We observed high rates of correct maintenance dose (90%), administration frequency (88%), and serum monitoring (74%). Loading doses (43%), adequate serum monitoring timing (43%), correction of dose because of inadequate levels (32%) were less adequate. Overall, only three (3%) treatments were adequate for all evaluated items. CONCLUSION: Glycopeptide indications were adequate. However, the quality of prescription can be improved and should focus on loading doses and serum monitoring.


Asunto(s)
Antibacterianos , Infecciones Bacterianas/tratamiento farmacológico , Infección Hospitalaria/tratamiento farmacológico , Prescripciones de Medicamentos/estadística & datos numéricos , Revisión de la Utilización de Medicamentos , Hospitales/estadística & datos numéricos , Teicoplanina , Vancomicina , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Relación Dosis-Respuesta a Droga , Monitoreo de Drogas , Farmacorresistencia Microbiana , Francia , Adhesión a Directriz , Hospitales Privados/estadística & datos numéricos , Hospitales Públicos/estadística & datos numéricos , Hospitales Universitarios/estadística & datos numéricos , Humanos , Infusiones Intravenosas , Estudios Prospectivos , Teicoplanina/administración & dosificación , Teicoplanina/sangre , Teicoplanina/uso terapéutico , Vancomicina/administración & dosificación , Vancomicina/sangre , Vancomicina/uso terapéutico , Resistencia a la Vancomicina
7.
Rev Mal Respir ; 13(5): 521-2, 1996 Oct.
Artículo en Francés | MEDLINE | ID: mdl-8999481

RESUMEN

Resistance to the activation of protein C is a recently discovered constitutional anomaly of coagulation which is responsible for thromboembolic events in young subjects. We report a case in a 26 year old man who presented with pulmonary embolus. Laboratory data was characterised by an absence of any lengthening of the activated cephaline time after adding purified activated exogenous Protein C. The confirmation of this anomaly is provided by the evidence of a mutation Arg 506 to Gln of Factor 5. The outcome is favourable with treatment by Heparin then by anti-Vitamin K.


Asunto(s)
Deficiencia de Proteína C , Embolia Pulmonar/etiología , Adulto , Arginina/genética , Codón/genética , Factor V/genética , Glutamina/genética , Humanos , Masculino , Mutación/genética , Tiempo de Tromboplastina Parcial , Proteína C/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...